News
-
Aptar has announced its acquisition of Noble International, which specializes in training devices and patient onboarding for drug delivery devices, including inhalers. Noble makes respiratory trainers for both MDIs and DPIs with a variety of… Read more . . .
-
Liquidia Technologies has announced the appointment of AbbVie VP of Global Commercial Development Katie Rielly-Gauvin to its board of directors for a term that will extend until company’s 2020 annual meeting. Prior to her position at… Read more . . .
-
After having been notified that CHMP was likely to issue a negative opinion regarding its MAA for Linhaliq dual release inhaled ciprofloxacin for the treatment of P. aeruginosa lung infections in patients with non-cystic fibrosis… Read more . . .
-
Inhaled nitric oxide developer Third Pole Therapeutics has announced the appointment of Bill Athenson as its new Chief Executive Officer, succeeding founding CEO David Zapol. Athenson most recently served as CEO of Three Lakes Partners;… Read more . . .
-
Inhaled drug developer Vectura has announced the appointment of former Catalent executive Will Downie as CEO and Executive Director. Downie was most recently Senior VP, Global Sales and Marketing at Catalent and previously served in… Read more . . .
-
CDMO Micro-Sphere has announced an investment of 3.5 million CHF (~$3.5 million) that will include the addition of a fifth spray drying line to its GMP facility in Switzerland. The new line should be in… Read more . . .
-
Dry powder inhaler developer Iconovo has announced that the company will invest approximately 20 million SEK over about 3 years to develop a new platform for development of generic versions of Ellipta DPI products. The… Read more . . .
-
Bryn Pharma, which recently announced that it would use Aptar’s Bidose nasal device for delivery of its BRYN-NDS1C intranasal epinephrine, said that it has raised $17.5 million that it will use to prepare for US… Read more . . .
-
TFF Pharmaceuticals, which is developing DPI formulations based on its thin film freezing (TFF) technology, has announced an initial public offering of 4,400,000 shares of common stock at $5.00 per share. Earlier this year TFF… Read more . . .
-
Medical Developments International (MDI) has announced data from multiple European studies demonstrating the benefits of MDI’s Penthrox methoxyflurane inhaler for the treatment of pain from acute trauma. Among the findings announced, Penthrox was shown to… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK